Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2017-01-03 Investor Presentation
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
Corporate Presentation 15 pages 1.5MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation from Antisense Therapeutics Ltd dated January 2017. It contains forward-looking statements, detailed descriptions of drug development programs, clinical trial results, corporate overview, and financial highlights. The content is structured as a presentation with slides, including pipeline updates, clinical trial data, market opportunities, and corporate information. There is no indication that this is an official annual or interim report, audit report, or regulatory filing. The document is not a transcript of a call, nor is it a voting result or legal proceeding. It is clearly designed to inform investors about the company's strategy, clinical progress, and market potential, which aligns with the definition of an Investor Presentation (IP). The length and detail also support this classification rather than a brief factsheet or announcement. Therefore, the most appropriate classification is Investor Presentation (IP).
2017-01-03 English
Change of Director's Interest Notice - (RM, MD, GM, WG) 8 pages 60.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by company directors, including shares and options acquired or disposed, nature of changes, and dates. The document is a formal notification of personal share transactions by company directors. It does not contain financial statements, earnings data, or management discussion. It is not an announcement of a report but the actual notice of director dealings. Therefore, it fits the category of Director's Dealing (DIRS). The document length is substantial and contains detailed transaction data, supporting a high confidence classification.
2016-12-20 English
Results of Rights and Bonus Issue 1 page 360.3KB
Capital/Financing Update Classification · 95% confidence The document is a company announcement regarding the results of a rights and bonus issue, specifically detailing the issuance of options and the updated securities profile. It includes information about the number of options issued, funds raised, and the securities profile post-issuance. There is no indication that this is a full financial report, audit, or earnings release. The content focuses on capital structure changes due to the issuance of new options and shares. The document length is short (1255 characters), and it is not a report publication announcement or certification. Therefore, the document fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2016-12-19 English
Appendix 3B - Issue of Securities 15 pages 306.8KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including classes of securities, number issued, terms, issue price, purpose, shareholder approvals, and quotation application to the ASX (Australian Securities Exchange). Appendix 3B is a standard form used in Australian market disclosures specifically for announcing new issues of securities and applying for their quotation. The content is regulatory in nature, focused on capital raising and securities issuance, not a financial report or earnings release. It is not a full financial report but a formal announcement of a capital/financing event. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed data, confirming it is not a mere announcement of a report but the actual issuance announcement.
2016-12-19 English
Appendix 3C 3 pages 26.8KB
Transaction in Own Shares Classification · 100% confidence The document is titled 'Appendix 3C Announcement of buy-back' and contains detailed information about a selective buy-back of shares by Antisense Therapeutics Limited. It includes specifics such as the type of buy-back, class of shares, voting rights, number of shares, shareholder approval, and reasons for the buy-back. The document references compliance with the Corporations Act and is structured as a formal announcement to the ASX (Australian Securities Exchange). The content is focused on the company's share repurchase activity rather than financial results, management changes, or other report types. Given the detailed nature of the buy-back information and the formal announcement format, this fits the category of a Transaction in Own Shares (POS) filing, which covers share repurchase announcements and related disclosures.
2016-12-07 English
Change of Director's Interest Notice (RM) 2 pages 22.5KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details a director's direct and indirect interests in securities, including the number of shares held before and after a change, the nature of the change (on-market acquisition), and the value of the transaction. This type of document is a formal notification of personal share transactions by a company director. It does not contain financial performance data, management discussion, or other report content. Therefore, it fits the category of Director's Dealing (DIRS). The document length is under 5,000 characters and is a specific regulatory form for insider trading disclosures, confirming the classification.
2016-12-04 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.